retatrutide dosing phase 2 trial isn't a GLP-1. It's not a dual agonist. It's a triple hormone receptor agonist — activating GIP, GLP-1, and glucagon simultaneously. Three receptors. Three mechanisms. One protocol. Swipe to see what ESC 2024: Retatrutide improves lipid

This is particularly relevant as public demand for these medications grows and payers navigate coverage policies for both anti-obesity and anti-diabetic indications

The risk of hypoglycaemia is typically minor

In addition, a head-to-head trial of semaglutide and liraglutide was conducted in the STEP 8 trial, with a mean weight loss of 17.1% in the semaglutide group, which was significantly more effective than liraglutide (mean weight loss of 6.6%)

While the clinical evaluation of GLP-1MK-801 for weight loss awaits, efforts to broaden the scope of developing peptide-mediated targeting of ion channels are encouraged and should not be restricted to metabolic diseases

That call belongs entirely to the reviewing clinician

Learn more about the experts behind our content on our Health Expert Team page.